Gene, Cell, & RNA Therapy Landscape Report

The Gene, Cell, & RNA Therapy Landscape report, created in partnership with Citeline, is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Q2: RNA therapies Rytelo, mRESVIA approved in U.S.

In Q2 2024:

  • RNA therapies for myelodysplastic syndrome and respiratory syncytial virus (RSV) were approved in the U.S.

  • 76 gene therapy trials were initiated—a 25% increase since Q1

  • $266.3 million, an 11% increase over the previous quarter, was raised

Report Archives

2024 Archive

Read all available reports from 2024.

2023 Archive

Read all the landscape reports from 2023.

2022 Archive

Read all the landscape reports from 2022.

2021 Archive

Read all the reports from 2021 here.

2024

Register for the ASGCT Policy Summit

September 23-24, 2024 | Washington, D.C.